Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

OBJECTIVES:

Primary

• Determine the safety of ultraviolet-B light therapy and allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies by demonstrating 100-day mortality no greater than 15% and 1-year mortality no greater than 40%.
• Determine the frequency of treatment-related toxicity leading to death and frequency of disease relapse resulting in death in patients treated with this regimen.
• Determine the incidence and severity of acute and chronic graft-versus-host disease in patients treated with this regimen.

Secondary

• Determine the rates of donor allogeneic hematologic engraftment in patients treated with this regimen.
• Determine the rate and quality of immune reconstitution in the peripheral blood and the composition of immune cells in the skin before and after transplantation in these patients.
• Determine the event-free and overall survival of patients treated with this regimen.

OUTLINE:

• Preparative regimen: Patients receive fludarabine IV over 30 minutes on days -8 to -4 and cyclophosphamide IV over 1 hour on days -3 to -2. Patients also receive anti-thymocyte globulin IV over 4 hours on days -2 to -1. Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days.
• Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
• Graft-versus-host disease prophylaxis: Patients receive oral cyclosporine on days -1 to 100 and methylprednisolone (oral or IV) on days 5-15.
• Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.

Donor lymphocyte infusion is performed per institutional guidelines for patients in whom emerging donor chimerism post allogeneic PBSC transplantation is not progressing (consistently below 50% during first 3 months), for whom donor chimerism is receding (to below 25%) despite cessation of cyclosporine, or who relapse within 24 months after allografting.

Patients are followed at least monthly for 3 months and then at 6, 12, 18, and 24 months.

PROJECTED ACCRUAL: A total of 23-36 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of any of the following hematologic malignancies:

• Acute myeloid leukemia (AML) meeting any of the following criteria:

• First complete remission with high-risk karyotype

• Translocations t(15;17) allowed only if failed first-line induction therapy OR molecular evidence of persistent disease exists
• Translocations t(8;21) and inv(16) allowed only if failed first-line induction therapy
• Second or subsequent complete remission
• Minimal residual disease*
• Acute lymphoblastic leukemia meeting any of the following criteria:

• Failed induction therapy and has minimal residual disease* by salvage therapy
• First complete remission with high-risk karyotype (e.g., t[4;11] or t[9;22])
• Relapsed disease allowed provided a second or subsequent complete remission or minimal residual disease* is achieved
• Chronic myelogenous leukemia meeting any of the following criteria:

• Persistent or relapsed disease after 1 year of imatinib mesylate therapy
• Accelerated phase or blast crisis

• Blast crisis allowed after reinduction chemotherapy places disease in chronic phase
• Myelodysplastic syndromes meeting any of the following criteria:

• Refractory to medical management
• Cytogenetic abnormalities predictive of transformation into acute leukemia, including 5q-, 7q-, monosomy 7 and trisomy 8, or evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation)
• Non-Hodgkin's lymphoma or Hodgkin's lymphoma meeting any of the following criteria:

• Beyond first complete remission or failed primary induction therapy and demonstrated sensitivity to therapy during the 6 months before transplantation
• Recurrent disease after autologous stem cell transplantation

• Must be at least 3 months posttransplantation
• Cyclin D1+ mantle cell lymphoma allowed after induction therapy and in first remission
• Multiple myeloma meeting either of the following criteria:

• Refractory or relapsed disease
• Residual disease after autologous transplantation
• Chronic lymphocytic leukemia (CLL) meeting all of the following criteria:

• Peripheral blood absolute lymphocyte count greater than 5,000/mm^3
• Small to moderate size lymphocytes and less than 55% pro-lymphocytes, atypical lymphocytes, or lymphoblasts morphologically
• B-cell or T-cell
• Myeloproliferative disorders, including myelofibrosis

• Philadelphia negative
• Availability of a HLA-A, B, and DR identical family donor OR HLA-A, B, and DR genetically matched unrelated donor
• Must meet 1 of the following criteria:

• At least 55 years of age at time of transplantation
• Received extensive prior therapy (i.e., more than 1 year of alkylator therapy or more than 2 different prior salvage regimens) or stem cell transplantation with myeloablative conditioning (either autologous or allogeneic)
• Presenting with comorbid condition (e.g., abnormal cardiac, pulmonary, or renal function and/or prior life-threatening infection) that precludes eligibility for enrollment in allogeneic transplantation protocols with full ablation conditioning
• No active CNS disease NOTE: *Defined as having no circulating blasts, absolute neutrophil count greater than 1,000/mm3 and less than 10% blasts in bone marrow at least 3 weeks after last systemic chemotherapy

PATIENT CHARACTERISTICS:

Age

• See Disease Characteristics
• Over 18

Performance status

• ECOG 0-2

Life expectancy

• At least 3 months

Hematopoietic

• See Disease Characteristics

Hepatic

• Bilirubin no greater than 2.0 mg/dL
• ALT/AST no greater than 4 times normal

Renal

• See Disease Characteristics
• Creatinine less than 2.0 mg/dL OR
• Creatinine clearance at least 50 mL/min

Cardiovascular

• See Disease Characteristics
• Normal cardiac function by echocardiogram or radionuclide scan
• Shortening fraction or ejection fraction at least 40% of normal

Pulmonary

• See Disease Characteristics
• DLCO at least 60%
• FEV_1 greater than 50% of predicted
• Pulse oximetry greater than 85%

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No uncontrolled active infection

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics
• At least 2 weeks since prior biologic response modifiers, signal transduction inhibitors, or monoclonal antibodies

Chemotherapy

• See Disease Characteristics
• At least 4 weeks since prior systemic conventional chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• Recovered from prior therapy
• No concurrent sun block/sunscreen or any cosmetic that may act as a sunscreen (e.g., lotion with SPF) on the days of scheduled ultraviolet-B light therapy